Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.34 |
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390283 | 1.00 | HSD17B10 (0.38) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL13860171 | 1.00 | HSD17B10 (0.38) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL4388287 | 1.00 | HSD17B10 (0.38) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL336027 | 0.89 | RIPK1 (0.34) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL345736 | 0.89 | RIPK1 (0.34) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL617316 | 0.89 | RIPK1 (0.34) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL1098205 | 0.89 | RIPK1 (0.34) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL345737 | 0.89 | RIPK1 (0.34) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL5002190 | 0.81 | DPP4 (0.40) | HSD17B10LMNACYP2C19RIPK1DPP4 | |
| SCHEMBL1920132 | 0.81 | DPP4 (0.40) | HSD17B10LMNACYP2C19RIPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526771-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4074701-B1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEMICAL LTD (KR) | 2023-12-13 | — | — | EP | disclosed |
| EP-2710005-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014022569-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012158764-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | HSD17B10 4438/4885LMNA 1793/4885CYP2C19 1676/4885 |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | HSD17B10 2089/4885LMNA 2855/4885CYP2C19 817/4885 |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | CYP19A1, HSD17B11, CYP51A1 | HSD17B10 254/4885LMNA 3572/4885CYP2C19 32/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HSD17B10 4445/4885LMNA 4459/4885CYP2C19 2684/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | HSD17B10 4511/4885LMNA 3632/4885CYP2C19 2537/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | HSD17B10 77/4885LMNA 3574/4885CYP2C19 811/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | HSD17B10 1928/4885LMNA 3845/4885CYP2C19 1878/4885 |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | HSD17B10 4195/4885LMNA 4391/4885CYP2C19 258/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | HSD17B10 141/4885LMNA 2744/4885CYP2C19 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.